

# Antoine G Van Der Heijden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6625528/publications.pdf>

Version: 2024-02-01

49  
papers

5,219  
citations

257450

24  
h-index

206112

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

5411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. <i>European Urology Focus</i> , 2022, 8, 995-1002.	3.1	6
2	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	1.9	158
3	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. <i>Journal of Personalized Medicine</i> , 2022, 12, 726.	2.5	2
4	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	3.1	4
5	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	1.9	1,152
6	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. <i>International Journal of Cancer</i> , 2021, 148, 981-987.	5.1	12
7	Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 377.	3.7	13
8	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. <i>Scientific Reports</i> , 2021, 11, 6132.	3.3	7
9	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	1.9	198
10	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	5.4	54
11	Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the "trials within cohorts" study ProBCI. <i>BMJ Open</i> , 2021, 11, e047256.	1.9	5
12	Orthotopic urinary diversions after radical cystectomy for bladder cancer: lessons learned last decade. <i>Current Opinion in Urology</i> , 2021, 31, 580-585.	1.8	3
13	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 802877.	4.8	5
14	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 440-448.	1.6	27
15	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	5.4	61
16	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
17	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. <i>Cancers</i> , 2020, 12, 2692.	3.7	29
18	Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. <i>Nature Reviews Urology</i> , 2020, 17, 513-525.	3.8	94

#	ARTICLE	IF	CITATIONS
19	Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. <i>Eur Urol</i> 2020;78:489-91. <i>European Urology</i> , 2020, 78, 492-493.	1.9	2
20	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100266.	1.7	10
21	Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?. <i>European Urology Oncology</i> , 2020, 3, 316-317.	5.4	6
22	Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial -NIMBUS-. <i>European Urology</i> , 2020, 78, 690-698.	1.9	76
23	European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update. <i>European Urology Oncology</i> , 2020, 3, 424-432.	5.4	28
24	Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100264.	1.7	8
25	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 51-60.	2.2	31
26	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. <i>Translational Research</i> , 2019, 208, 73-84.	5.0	5
27	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. <i>International Journal of Hyperthermia</i> , 2018, 34, 988-993.	2.5	14
28	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	1.9	1,241
29	Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. <i>BJU International</i> , 2017, 120, 12-24.	2.5	63
30	Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 539.e17-539.e29.	1.6	43
31	Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 68, 198.	2.8	0
32	Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 434-445.	2.5	29
33	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 64, 127-136.	2.8	67
34	The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 166.e1-166.e6.	1.6	39
35	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2016, 69, 1046-1052.	1.9	176
36	Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. <i>European Journal of Cancer</i> , 2016, 54, 131-138.	2.8	32

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 204-209.e2.	1.9	17
38	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015, 33, 1411-1417.	2.2	10
39	The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2014, 32, 651-9.	2.2	23
40	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	1.9	868
41	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	1.9	164
42	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
43	Radical Cystectomy in a Dutch University Hospital: Long-Term Outcomes and Prognostic Factors in a Homogeneous Surgery-Only Series. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 190-195.	1.9	14
44	Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 708-713.	0.4	56
45	The role of methylation in urological tumours. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 432-9.	0.2	4
46	The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis. <i>World Journal of Urology</i> , 2007, 25, 303-308.	2.2	10
47	Comparison of Hexaminolevulinate Based Flexible and Rigid Fluorescence Cystoscopy with Rigid White Light Cystoscopy in Bladder Cancer: Results of a Prospective Phase II Study. <i>European Urology</i> , 2005, 47, 319-322.	1.9	75
48	EFFECT OF HYPERTHERMIA ON THE CYTOTOXICITY OF 4 CHEMOTHERAPEUTIC AGENTS CURRENTLY USED FOR THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER: AN IN VITRO STUDY. <i>Journal of Urology</i> , 2005, 173, 1375-1380.	0.4	92
49	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	1